Biventricular assist devices and total artificial heart: Strategies and outcomes

Taiyo Kuroda; Chihiro Miyagi; Kiyotaka Fukamachi; Kiyotaka Fukamachi; Jamshid H. Karimov; Jamshid H. Karimov

doi:10.3389/fcvm.2022.972132

Frontiers in Cardiovascular Medicine (Jan 2023)

Biventricular assist devices and total artificial heart: Strategies and outcomes

Taiyo Kuroda,
Chihiro Miyagi,
Kiyotaka Fukamachi,
Kiyotaka Fukamachi,
Jamshid H. Karimov,
Jamshid H. Karimov

Affiliations

Taiyo Kuroda: Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States
Chihiro Miyagi: Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States
Kiyotaka Fukamachi: Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States
Kiyotaka Fukamachi: Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States
Jamshid H. Karimov: Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States
Jamshid H. Karimov: Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States

DOI: https://doi.org/10.3389/fcvm.2022.972132
Journal volume & issue: Vol. 9

Abstract

Read online

In contrast to the advanced development of the left ventricular assist device (LVAD) therapy for advanced heart failure, the mechanical circulatory support (MCS) with biventricular assist device (BVAD) and total artificial heart (TAH) options remain challenging. The treatment strategy of BVAD and TAH therapy largely depends on the support duration. For example, an extracorporeal centrifugal pump, typically referred to as a temporary surgical extracorporeal right ventricular assist device, is implanted for the short term with acute right ventricular failure following LVAD implantation. Meanwhile, off-label use of a durable implantable LVAD is a strategy for long-term right ventricular support. Hence, this review focuses on the current treatment strategies and clinical outcomes based on each ventricle support duration. In addition, the issue of heart failure post-heart transplantation (post-HT) is explored. We will discuss MCS therapy options for post-HT recipients.

Published in Frontiers in Cardiovascular Medicine

ISSN: 2297-055X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.frontiersin.org/journals/cardiovascular-medicine

About the journal

Abstract

Keywords